Dingwei Ye, MD
Fudan University Shanghai Cancer Center, Fudan University · Fudan University · Shanghai Cancer Center of Fudan University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Dingwei Ye, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 04:47 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT07567521 · A Study of TRC003 in the Treatment of Patients With Progressive PSMA-positive mCRPCC Ray Therapeutics · recruiting · Prostate Cancer · study chair
- Ph1/Ph2NCT06588179 · SHR-1501 Combined With SHR-2005 for High-Risk Non-Muscle Invasive Bladder Cancer Which is Not Completely Resectable by TURBtFudan University · not yet recruiting · NMIBC · principal investigator
- Ph2NCT06222125 · A Study of HB0025 Injection in Patients With Advanced Renal CancerHuabo Biopharm Co., Ltd. · unknown · Renal Cancer · principal investigator
- Ph2NCT05256472 · A Study of AK104 Monotherapy or AK104 Plus Axitinib in Advanced/Metastatic Renal Cell CarcinomaAkeso · completed · Renal Cell Carcinoma, First-line Treatment · principal investigator
- Ph2NCT04498702 · Study of Continuous APL-1202 Treatment in Subjects With High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Relapsed From Intravesical Chemo/BCG TherapyJiangsu Yahong Meditech Co., Ltd aka Asieris · completed · Non-muscle Invasive Bladder Cancer · principal investigator
- Ph3NCT04490993 · Safety and Efficacy of APL-1202 in Combination With Epirubicin Hydrochloride Versus Epirubicin Hydrochloride Alone in Intermediate and High-risk Chemo-refractory Non-muscle Invasive Bladder Cancer (NMIBC) PatientsJiangsu Yahong Meditech Co., Ltd aka Asieris · unknown · Non-muscle Invasive Bladder Cancer · principal investigator
- Ph3NCT03967977 · Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial CarcinomaBeiGene · active not recruiting · Urothelial Carcinoma · principal investigator
- Ph1/Ph2NCT03843918 · A Study on the Safety and Efficacy of LAE001 in the Treatment of Metastatic Prostate CancerLaekna Limited · terminated · Prostate Cancer Metastatic · principal investigator
- Ph2NCT03827837 · Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological TumorsJiangsu HengRui Medicine Co., Ltd. · unknown · Renal Cell Carcinoma, Urothelial Carcinoma, Cervical Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 04:47 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 04:47 UTC. The ranking covers the 200 most relevant of 12 PubMed records, and a shared surname and initials can bring in a namesake. All 12 on PubMed
- Sotorasib for Lung Cancers with KRAS p.G12C Mutation.N Engl J Med · 20211,561 citationsRCR 84.2
- KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors.N Engl J Med · 20201,444 citationsRCR 58.9
- Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer.N Engl J Med · 2020658 citationsRCR 27.4
- Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (EA2108).J Clin Oncol · 2022164 citationsRCR 10.6
- A phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignancies.Invest New Drugs · 201339 citationsRCR 1.0
- Phase II studies of two different schedules of dasatinib in bone metastasis predominant metastatic breast cancer: SWOG S0622.Breast Cancer Res Treat · 201634 citationsRCR 1.0
- Sharing in care: engaging care partners in the care and communication of breast cancer patients.Breast Cancer Res Treat · 201925 citationsRCR 1.3
- Do patient race and sex change surgeon recommendations for TKA?Clin Orthop Relat Res · 201524 citationsRCR 1.2
- A Randomized Trial of Fulvestrant, Everolimus, and Anastrozole for the Front-line Treatment of Patients with Advanced Hormone Receptor-positive Breast Cancer, SWOG S1222.Clin Cancer Res · 202210 citationsRCR 0.6
- SHARING Choices: Lessons Learned from a Primary-Care Focused Advance Care Planning Intervention.J Pain Symptom Manage · 202310 citationsRCR 1.9